3
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Neuroblastoma
2
Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Sarcoma
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Granuloma, Plasma Cell
1
Interventions
Cyclophosphamide
9
Biopsy
5
Specimen Handling
4
Prednisone
4
Nivolumab
4
Magnetic Resonance Spectroscopy
4
fludarabine
3
Vincristine
3
Etoposide
3
Doxorubicin
3
Brentuximab Vedotin
3
sodium-iodide symporter
2
pembrolizumab
2
fludarabine phosphate
2
cemiplimab
2
alectinib
2
X-Rays
2
Whole-Body Irradiation
2
Stem Cell Transplantation
2
Rituximab
2
Positron-Emission Tomography
2
Photons
2
Mycophenolic Acid
2
Immunoglobulin G
2
Filgrastim
2
Disulfides
2
Cyclosporine
2
10-propargyl-10-deazaaminopterin
2
treosulfan
1
talimogene laherparepvec
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Large-Cell, Anaplastic
×
ceritinib
×
1 year
×
Clear all
NCT05100134
2026-04-01
Managed Access Programs for LDK378, Ceritinib
Novartis
No longer available